Pravastatin + Pravastatin
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Therapeutic Equivalency
Conditions
Therapeutic Equivalency
Trial Timeline
Jul 1, 2003 → Jul 1, 2003
NCT ID
NCT00648544About Pravastatin + Pravastatin
Pravastatin + Pravastatin is a phase 1 stage product being developed by Viatris for Therapeutic Equivalency. The current trial status is completed. This product is registered under clinical trial identifier NCT00648544. Target conditions include Therapeutic Equivalency.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00648544 | Phase 1 | Completed |
| NCT00650221 | Phase 1 | Completed |
Competing Products
11 competing products in Therapeutic Equivalency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) | Johnson & Johnson | Phase 1 | 33 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| Amifostine + Carboplatin + Paclitaxel | AstraZeneca | Phase 2 | 52 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| etynodiol diacetate + etynodiol diacetate | Pfizer | Phase 1 | 32 |
| methylprednisolone + methylprednisolone | Pfizer | Phase 1 | 32 |
| Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine + Fesoterodine | Pfizer | Phase 1 | 32 |
| BAY98-7111 + Naproxen Sodium (Aleve, BAYH6689) + Diphenhydramine HCl + BAY98-7111 | Bayer | Phase 1 | 30 |
| Pravastatin + Pravastatin | Viatris | Phase 1 | 30 |
| Raxibacumab | Emergent BioSolutions | Phase 2/3 | 57 |
Other Products from Viatris
Revefenacin + Tiotropium + Revefenacin Placebo + Tiotropium PlaceboApproved
82
PregabalinApproved
82
Imiquimod + DiclofenacApproved
82
gabapentin 600 mg + gabapentin 1200 mg + gabapentin 1800 mg + diazepam 20 mgApproved
82
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsApproved
82